Read all posts

An End to Heart Disease? Not Quite

On Friday, investigators reported the results of a highly anticipated trial of a PCSK9 inhibitor called evolocumab (brand name Repatha). This medication reduced LDL levels to an almost unfathomable 30 mg/dl from about 90 mg/dl on average, which is typically considered low.

Read the article on Nytimes

Dr. Sears Comments:

Dr. Barry Sears
Not mentioned in the article is a recent article (Ravnskov et al BMJ Open
2016;6:e010401) that demonstrated there is no association and potentially an inverse association between LDL cholesterol and all-cause mortality.  If you are really interested in lowering cholesterol, then lowering insulin will decrease the production of cholesterol and lower LDL cholesterol.  However, the bottom line is the real driver of a heart attack is not LDL cholesterol, but increased inflammation.

Leave a Reply

Your email address will not be published. Required fields are marked *